Advertisement

Schizophrenia: One Name, Many Different Manifestations

Published:October 27, 2022DOI:https://doi.org/10.1016/j.mcna.2022.05.005

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Medical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McGrath J.
        • Saha S.
        • Chant D.
        • et al.
        Schizophrenia: a concise overview of incidence, prevalence, and mortality.
        Epidemiol Rev. 2008; 30: 67-76
        • Moreno-Küstner B.
        • Martín C.
        • Pastor L.
        Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses.
        PLoS One. 2018; 13: e0195687
        • Kahn R.S.
        • Sommer I.E.
        The neurobiology and treatment of first-episode schizophrenia.
        Mol Psychiatry. 2015; 20: 84-97
        • Häfner H.
        • Maurer K.
        • Löffler W.
        • et al.
        The epidemiology of early schizophrenia. Influence of age and gender on onset and early course.
        Br J Psychiatry Suppl. 1994; : 29-38
        • GBD 2017 Disease and Injury Incidence and Prevalence Collaborators
        Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet. 2018; 392: 1789-1858
        • Salomon J.A.
        • Vos T.
        • Hogan D.R.
        • et al.
        Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
        Lancet. 2012; 380: 2129-2143
        • Tandon R.
        • Nasrallah H.A.
        • Keshavan M.S.
        Schizophrenia, “just the facts” 4. Clinical features and conceptualization.
        Schizophr Res. 2009; 110: 1-23
        • Lieberman J.A.
        • Alvir J.M.
        • Koreen A.
        • et al.
        Psychobiologic correlates of treatment response in schizophrenia.
        Neuropsychopharmacology. 1996; 14: 13S-21S
        • Kane J.M.
        • Correll C.U.
        Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia.
        J Clin Psychiatry. 2019; 80 (IN18031AH1C)
        • Gerlinger G.
        • Hauser M.
        • De Hert M.
        • et al.
        Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions.
        World Psychiatry. 2013; 12: 155-164
        • Rhee T.G.
        • Rosenheck R.A.
        Does improvement in symptoms and quality of life in chronic schizophrenia reduce family caregiver burden?.
        Psychiatry Res. 2019; 271: 402-404
        • Hayes J.F.
        • Marston L.
        • Walters K.
        • et al.
        Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014.
        Br J Psychiatry. 2017; 211: 175-181
        • Hjorthøj C.
        • Stürup A.E.
        • McGrath J.J.
        • et al.
        Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.
        Lancet Psychiatry. 2017; 4: 295-301
        • Correll C.U.
        • Rubio J.M.
        • Kane J.M.
        What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?.
        World Psychiatry. 2018; 17: 149-160
        • Olfson M.
        • Stroup T.S.
        • Huang C.
        • et al.
        Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span.
        JAMA Psychiatry. 2021; 78: 876-885
        • American Psychiatric Association
        Diagnostic and statistical manual of mental disorders. 5th Edition, Text Revision (DSM-5-TR).
        American Psychiatric Publishing, Arlington (VA)2022
        • First M.
        • Williams J.
        • Karg R.
        • et al.
        Structured clinical Interview for DSM-5 disorders, clinician version (SCID-5-CV).
        American Psychiatric Association, Arlington (VA)2016
        • Keepers G.A.
        • Fochtmann L.J.
        • Anzia J.M.
        • et al.
        The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.
        Am J Psychiatry. 2020; 177: 868-872
        • Lieberman J.A.
        • Perkins D.
        • Belger A.
        • et al.
        The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches.
        Biol Psychiatry. 2001; 50: 884-897
        • Citrome L.
        Differential diagnosis of psychosis. A brief guide for the primary care physician.
        Postgrad Med. 1989; 85 (279-280): 273-274
        • Farooq S.
        • Agid O.
        • Foussias G.
        • et al.
        Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification.
        Schizophr Bull. 2013; 39: 1169-1172
        • Tiwari A.K.
        • Zai C.C.
        • Müller D.J.
        • et al.
        Genetics in schizophrenia: where are we and what next?.
        Dialogues Clin Neurosci. 2010; 12: 289-303
        • Sullivan P.F.
        • Agrawal A.
        • Bulik C.M.
        • et al.
        Psychiatric Genomics: An Update and an Agenda.
        Am J Psychiatry. 2018; 175: 15-27
        • Schizophrenia Working Group of the Psychiatric Genomics Consortium
        Biological insights from 108 schizophrenia-associated genetic loci.
        Nature. 2014; 511: 421-427
        • Kahn R.S.
        • Sommer I.E.
        • Murray R.M.
        • et al.
        Schizophrenia.
        Nat Rev Dis Primers. 2015; 1: 15067
        • Robinson N.
        • Bergen S.E.
        Environmental Risk Factors for Schizophrenia and Bipolar Disorder and Their Relationship to Genetic Risk: Current Knowledge and Future Directions.
        Front Genet. 2021; 12: 686666
        • Howes O.D.
        • Murray R.M.
        Schizophrenia: an integrated sociodevelopmental-cognitive model.
        Lancet. 2014; 383: 1677-1687
        • Demjaha A.
        • Egerton A.
        • Murray R.M.
        • et al.
        Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.
        Biol Psychiatry. 2014; 75: e11-e13
        • Stahl S.M.
        Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate.
        CNS Spectr. 2018; 23: 187-191
        • Tariot P.N.
        • Cummings J.L.
        • Soto-Martin M.E.
        • et al.
        Trial of Pimavanserin in Dementia-Related Psychosis.
        N Engl J Med. 2021; 385: 309-319
        • Keshavan M.S.
        • Collin G.
        • Guimond S.
        • et al.
        Neuroimaging in Schizophrenia.
        Neuroimaging Clin N Am. 2020; 30: 73-83
        • van Erp T.G.M.
        • Hibar D.P.
        • Rasmussen J.M.
        • et al.
        Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium.
        Mol Psychiatry. 2016; 21: 585
        • van Erp T.G.M.
        • Walton E.
        • Hibar D.P.
        • et al.
        Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium.
        Biol Psychiatry. 2018; 84: 644-654
        • Kühn S.
        • Gallinat J.
        Resting-state brain activity in schizophrenia and major depression: a quantitative meta-analysis.
        Schizophr Bull. 2013; 39: 358-365
        • Kraguljac N.V.
        • McDonald W.M.
        • Widge A.S.
        • et al.
        Neuroimaging Biomarkers in Schizophrenia.
        Am J Psychiatry. 2021; 178: 509-521
        • Owen M.J.
        • Sawa A.
        • Mortensen P.B.
        Schizophrenia.
        Lancet. 2016; 388: 86-97
        • Davidson M.
        The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia.
        Dialogues Clin Neurosci. 2018; 20: 215-221
        • Vermeulen J.
        • van Rooijen G.
        • Doedens P.
        • et al.
        Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.
        Psychol Med. 2017; 47: 2217-2228
        • Taipale H.
        • Tanskanen A.
        • Mehtälä J.
        • et al.
        20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20).
        World Psychiatry. 2020; 19: 61-68
        • Leucht S.
        • Corves C.
        • Arbter D.
        • et al.
        Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.
        Lancet. 2009; 373: 31-41
        • Leucht S.
        • Cipriani A.
        • Spineli L.
        • et al.
        Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
        Lancet. 2013; 382: 951-962
        • Huhn M.
        • Nikolakopoulou A.
        • Schneider-Thoma J.
        • et al.
        Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.
        Lancet. 2019; 394: 939-951
        • Levi L.
        • Bar Haim M.
        • Burshtein S.
        • et al.
        Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort.
        Eur Neuropsychopharmacol. 2020; 32: 131-135
        • O’Keeffe D.
        • Kinsella A.
        • Waddington J.L.
        • et al.
        20-Year Prospective, Sequential Follow-Up Study of Heterogeneity in Associations of Duration of Untreated Psychosis With Symptoms, Functioning, and Quality of Life Following First-Episode Psychosis.
        Am J Psychiatry. 2022; 179: 288-297
        • Malla A.
        Reducing Duration of Untreated Psychosis: The Neglected Dimension of Early Intervention Services.
        Am J Psychiatry. 2022; 179: 259-261
        • Zhu Y.
        • Krause M.
        • Huhn M.
        • et al.
        Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses.
        Lancet Psychiatry. 2017; 4: 694-705
        • Howes O.D.
        • McCutcheon R.
        • Agid O.
        • et al.
        Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
        Am J Psychiatry. 2017; 174: 216-229
        • Faden J.
        • Citrome L.
        Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.
        Expert Opin Pharmacother. 2019; 20: 11-24
        • de Leon J.
        • Schoretsanitis G.
        • Smith R.L.
        • et al.
        An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.
        Pharmacopsychiatry. 2022; 55: 73-86
        • Correll C.U.
        • Rubio J.M.
        • Inczedy-Farkas G.
        • et al.
        Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.
        JAMA Psychiatry. 2017; 74: 675-684
        • Wagner E.
        • Kane J.M.
        • Correll C.U.
        • et al.
        Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.
        Schizophr Bull. 2020; 46: 1459-1470
        • Kane J.M.
        • Kishimoto T.
        • Correll C.U.
        Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.
        World Psychiatry. 2013; 12: 216-226
        • Leucht S.
        • Heres S.
        Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
        J Clin Psychiatry. 2006; 67: 3-8
        • Kishimoto T.
        • Hagi K.
        • Kurokawa S.
        • et al.
        Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies.
        Lancet Psychiatry. 2021; 8: 387-404
        • Tiihonen J.
        • Haukka J.
        • Taylor M.
        • et al.
        A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
        Am J Psychiatry. 2011; 168: 603-609
        • Rubio J.M.
        • Taipale H.
        • Tanskanen A.
        • et al.
        Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study.
        Schizophr Bull. 2021; 47: 1611-1620
        • Koblan K.S.
        • Kent J.
        • Hopkins S.C.
        • et al.
        A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
        N Engl J Med. 2020; 382: 1497-1506
        • Brannan S.K.
        • Sawchak S.
        • Miller A.C.
        • et al.
        Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
        N Engl J Med. 2021; 384: 717-726
        • Fleischhacker W.W.
        • Podhorna J.
        • Gröschl M.
        • et al.
        Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study.
        Lancet Psychiatry. 2021; 8: 191-201
        • Tandon R.
        • Nasrallah H.A.
        • Keshavan M.S.
        Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future.
        Schizophr Res. 2010; 122: 1-23
        • Janssen H.
        • Maat A.
        • Slot M.I.E.
        • et al.
        Efficacy of psychological interventions in young individuals at ultra-high risk for psychosis: A naturalistic study.
        Early Interv Psychiatry. 2021; 15: 1019-1027
        • Bighelli I.
        • Rodolico A.
        • García-Mieres H.
        • et al.
        Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis.
        Lancet Psychiatry. 2021; 8: 969-980